HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.
The only producer of quality-controlled redox variants of HMGB1
Featured news
The role of High Mobility Group Box Protein 1 (HMGB1) is increasingly emerging in diabetes-associated complications, particularly diabetic encephalopathy (DE) and diabetic kidney disease (DKD).
High-Mobility Group Box-1 protein (HMGB1) plays a core role in the link between ulcerative colitis (UC) and colorectal cancer (CRC), particularly in colitic carcinoma.
HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.
Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…
Disulfide HMGB1
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…
Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…
From our LinkedIn profile
Featured Products
About us
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…
